Current filters:


Popular Filters

7894 to 7918 of 8819 results

FDA committee backs Affymax CKD drug


The US Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) voted 15 to one,…

AffymaxNephrology and HepatologyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Mixed views on drospirenone OCs


The majority of members of the US Food and Drug Administration’s Reproductive Health Drugs Advisory…

BayerDrospirenone and EstradiolNorth AmericaPharmaceuticalRegulationReproductiveWomen's HealthYasminYaz

Overactive bladder gel gets FDA nod


The US Food and Drug Administration (FDA) has approved US drugmaker Antares Pharma’s (NYSE Amex:…

Antares PharmaGenito-urinaryNorth AmericaOxybutyninPharmaceuticalRegulationWatson Pharmaceuticals

Breast cancer therapy news at SABCS


This year’s CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in Texas, USA, heard of developments…

AfinitorGenerex BiotechnologyNovartisOncologypertuzumabPharmaceuticalResearchRoche

FDA reviews Pradaxa bleeding risk


Post-marketing reports of serious bleeding events in patients taking Pradaxa (dabigatran etexilate mesylate),…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

Australia to improve therapeutics regulation


The Australian government said yesterday that it will introduce a comprehensive package of reforms for…

Asia-PacificMarkets & MarketingPharmaceuticalRegulation

Sinclair IS buys derma company


UK specialty drugmaker Sinclair IS Pharma plc (AIM: SPH.L) has entered into an agreement to acquire USA-based…

Advanced Bio-TechnologiesDermatologicalsKelo-coteMergers & AcquisitionsPharmaceuticalSinclair IS Pharma

MAbs largest class of biotherapeutics


Monoclonal antibodies (MAbs) were the fastest growing segment in the global pharmaceutical market in…

BiotechnologyMarkets & Marketing

Chinese pharma growth forecasts


Sustained double-digit growth in the Chinese pharmaceutical market from 2011 is forecast by UK-based…

Asia-PacificMarkets & MarketingPharmaceutical

AstraZeneca expands in China, cuts back in USA


It was a busy couple of days for Anglo-Swedish drug major AstraZeneca (LSE: AZN), with the company yesterday…

Asia-PacificAstraZenecaGenericsGuangdong BeiKang PharmaManagementMergers & AcquisitionsNorth AmericaPharmaceutical

FDA plans biosimilars user fee talks


The US Food and Drug Administration has published a Federal Register notice announcing a December 16…

BiotechnologyFinancialGenericsNorth AmericaRegulation

NICE wants more data on Daxas


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today issued final…

DaxasEuropeMerck & CoPharmaceuticalPricingRegulationRespiratory and Pulmonary

Dendreon cashes in Victrelis royalty


US pharma company Dendreon (Nasdaq: DNDN) says that it has agreed to sell for $125 million in cash its…

Anti-viralsBiotechnologyDendreonFinancialLicensingMerck & CoOncologyPharmaceuticalProvengeVictrelis

Theratechnologies to quit COPD program


Canada-based Theratechnologies (TSX: TH.TO) revealed yesterday that it is discontinuing its muscle wasting…

EgriftaFinancialNephrology and HepatologyPharmaceuticalResearchRespiratory and PulmonarytesamorelinTheratechnologies

Voraxaze out-licensed in Japan


UK health care firm BTG (LSE: BGC) says that it has licensed the Japanese rights to glucarpidase (which…

Asia-PacificBTGglucarpidaseLicensingOhara PharmaceuticalOncologyPharmaceuticalVoraxaze

Diabetes Rxing in China and S Korea


Dipeptidyl peptidase IV (DPP-IV) inhibitors are prescribed more commonly for the treatment of type 2…

Asia-PacificDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisPharmaceuticalPricing

EMA and EFPIA debate modelling


Modelling and simulation methodology provides an opportunity to improve the efficiency of pharmaceutical…


China to strengthen drug safety


China’s State Council (Cabinet) this week approved a blueprint to establish a credit rating system…


Generic strategic alliances


The generic drugs sector’s role as the provider of affordable drugs has widely benefitted public…

GenericsMergers & Acquisitions

Biogen Idec forms JV with Korea’s Samsung for biosimilars


US biotechnology firm Biogen Idec (Nasdaq: BIIB) has entered into an agreement with Korea’s largest…

Biogen IdecSamsung BioLogics

FDA eases REMS requirements for Amgen’s Nplate and GSK’s Promacta


The US Food and Drug Administration says that an agency initiated review of the current information has…

AmgenBiotechnologyGlaxoSmithKlineNorth AmericaNplatePharmaceuticalPromactaRare diseasesRegulation

More cancer and HIV drugs added to Australian PBS


More than 160,000 patients will benefit directly from changes to Australia’s Pharmaceutical Benefits…

AmgenAnti-viralsAsia-PacificGilead SciencesOncologyPharmaceuticalPrezistaPricingRegulationXgeva

Merck & Co commits $1.5 billion to R&D in China over next five years


Adding to the flow of pharmaceutical investment into the BRIC (Brazil, Russia, India and China) countries,…

Asia-PacificFinancialMerck & CoPharmaceuticalResearch

Novartis in licensing deal with Cellectis; pays milestone to GenVec


Paris, France-based Cellectis genome engineering specialist (Alternext: ALCLS) has signed a license agreement…


7894 to 7918 of 8819 results

Back to top